GBR-1372 (Glenmark Pharmaceuticals)

N/A

Report date: 2026/03/19 16:46:17

Base Information

Drug NameGBR-1372 (Glenmark Pharmaceuticals)

Drug Alias NameGBR-1372

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsEpidermal growth factor receptor erbB1 antagonists

TargetsT cell surface glycoprotein CD3Epidermal growth factor receptor erbB1

Therapy Area/IndicationsColorectal NeoplasmsCarcinoma, Squamous Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesGlenmark Pharmaceuticals Ltd

China Registration ClassN/A

Develop Information

Active CompaniesGlenmark Pharmaceuticals Ltd

Inactive CompaniesN/A

Active IndicationsColorectal NeoplasmsCarcinoma, Squamous Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A